According to Steel et al., community-acquired pneumonia (CAP) is described as an acute infection of the lung parenchyma acquired in the community. It is most commonly bacterial in nature and is associated with clinical and/or radiological evidence of consolidation of part or parts of one or both lungs. The most commonly identified pathogens are Streptococcus pneumoniae, Haemophilus influenzae, a typical bacteria (i.e., Chlamydia pneumoniae, Mycoplasma pneumoniae, Legionella sp).
The diagnosis of CAP is based on the presence of clinical features and is supported by imaging of the lungs, usually by chest radiography. Various sign and symptoms include fever, cough, sputum production, pleuritic chest pain, dyspnea, tachypnea, and tachycardia. Older patients and those who are immune-compromised may not exhibit typical symptoms, such as fever. However, most patients present with at least one respiratory symptom, such as acute functional or cognitive decline.
Many studies have suggested that the incidence of CAP is slightly higher in males as compared to females.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/community-acquired-bacterial-pneumonia-cabp-market
The Community-Acquired Bacterial Pneumonia (CABP) market report also covers emerging drugs, current treatment practices, Community-Acquired Bacterial Pneumonia (CABP) market share of the individual therapies, current and forecasted Community-Acquired Bacterial Pneumonia (CABP) Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Community-Acquired Bacterial Pneumonia (CABP) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Community-Acquired Bacterial Pneumonia (CABP) Market Key Facts
According to the European Lung White Book, approximately 3,370,000 cases of CAP are reported annually in the European Union with 1 million hospitalizations. Furthermore, the adult incidence of CAP in Europe ranges from 1.7–11.6 cases/1,000 people/year.
The Center for Disease Control and Prevention (CDC) estimates that drug-resistant bacteria causes 2 million illnesses and approximately 23,000 deaths each year in the United States. The main bacteria causing CABP (Streptococcus pneumonia), is responsible for 1.2 million infections and 7,000 deaths annually.
Key Benefits of Community-Acquired Bacterial Pneumonia (CABP) Market Report
-
Community-Acquired Bacterial Pneumonia (CABP) market report provides an in-depth analysis of Community-Acquired Bacterial Pneumonia (CABP) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
-
The Community-Acquired Bacterial Pneumonia (CABP) market report will help in developing business strategies by understanding the Community-Acquired Bacterial Pneumonia (CABP) Market trends & developments, key players and future market competition that will shape and drive the Community-Acquired Bacterial Pneumonia (CABP) market in the upcoming years.
-
The Community-Acquired Bacterial Pneumonia (CABP) market report covers Community-Acquired Bacterial Pneumonia (CABP) current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Community-Acquired Bacterial Pneumonia (CABP) market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Community-Acquired Bacterial Pneumonia (CABP) Market
The Community-Acquired Bacterial Pneumonia (CABP) market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Community-Acquired Bacterial Pneumonia (CABP) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Community-Acquired Bacterial Pneumonia (CABP) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Community-Acquired Bacterial Pneumonia (CABP) Epidemiology
The Community-Acquired Bacterial Pneumonia (CABP) epidemiology section covers insights about historical and current Community-Acquired Bacterial Pneumonia (CABP) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Community-Acquired Bacterial Pneumonia (CABP) Drugs Uptake and Key Market Players
The Community-Acquired Bacterial Pneumonia (CABP) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Community-Acquired Bacterial Pneumonia (CABP) market or expected to get launched in the market during the study period. The analysis covers Community-Acquired Bacterial Pneumonia (CABP) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of community-acquired Bacterial Pneumonia (CABP) market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and expected launch of emerging therapies during the forecast period of 2020–2030.
Some of the key players in the Community-Acquired Bacterial Pneumonia (CABP) market includes:
Paratek Pharmaceuticals
Melinta Therapeutics
And many others
Drugs Covered
Nuzyra
Baxdela
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Community-Acquired Bacterial Pneumonia (CABP) Competitive Intelligence Analysis
4. Community-Acquired Bacterial Pneumonia (CABP) Market Overview at a Glance
5. Community-Acquired Bacterial Pneumonia (CABP) Disease Background and Overview
6. Community-Acquired Bacterial Pneumonia (CABP) Patient Journey
7. Community-Acquired Bacterial Pneumonia (CABP) Epidemiology and Patient Population
8. Community-Acquired Bacterial Pneumonia (CABP) Treatment Algorithm, Current Treatment, and Medical Practices
9. Community-Acquired Bacterial Pneumonia (CABP) Unmet Needs
10. Key Endpoints of Community-Acquired Bacterial Pneumonia (CABP) Treatment
11. Community-Acquired Bacterial Pneumonia (CABP) Marketed Products
12. Community-Acquired Bacterial Pneumonia (CABP) Emerging Therapies
13. Community-Acquired Bacterial Pneumonia (CABP) Seven Major Market Analysis
14. Attribute Analysis
15. Community-Acquired Bacterial Pneumonia (CABP) Market Outlook (7 major markets)
16. Community-Acquired Bacterial Pneumonia (CABP) Access and Reimbursement Overview
17. KOL Views on the Community-Acquired Bacterial Pneumonia (CABP) Market.
18. Community-Acquired Bacterial Pneumonia (CABP) Market Drivers
19. Community-Acquired Bacterial Pneumonia (CABP) Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Related Reports
Community-Acquired Bacterial Pneumonia (CABP) Epidemiology Forecast to 2030
DelveInsight’s Community-Acquired Bacterial Pneumonia (CABP) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Community-Acquired Bacterial Pneumonia (CABP) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Community-Acquired Bacterial Pneumonia (CABP) Pipeline Insights, 2020
Community-Acquired Bacterial Pneumonia (CABP) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Community-Acquired Bacterial Pneumonia (CABP) market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/